Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 1R01AG075471-01 | U.S. NIH Grant/Contract | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute on Aging (NIA) | NIH |
Not provided
Not provided
Not provided
The TRIUMPH study is a randomized, double-blinded, 3-arm, parallel-group trial designed to compare the effects of anticholinergic bladder therapy versus a) beta-3-adrenergic agonist bladder therapy and b) no bladder pharmacotherapy on cognitive, urinary, and other aging-related functional outcomes in ambulatory older women with urgency-predominant urinary incontinence and either normal or mildly impaired cognitive function at baseline.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Anticholinergic bladder medication plus behavioral self-management education | Active Comparator | Tolterodine tartrate is a muscarinic receptor antagonist designed to treat urgency incontinence, urgency, and frequency associated with overactive bladder. Behavioral self-management education includes written education about timed urination, lifestyle changes, pelvic floor muscle exercises, and urge suppression. |
|
| Beta-3-adrenergic agonist medication plus behavioral self-management education | Active Comparator | Mirabegron, currently sold under the brand name Mybetriq by Astellas Pharma, is a selective beta-3-adrenergic receptor agonist approved for treatment of urgency urinary incontinence, urgency, and frequency associated with overactive bladder. Behavioral self-management education includes written education about timed urination, lifestyle changes, pelvic floor muscle exercises, and urge suppression. |
|
| Placebo medication plus behavioral self-management education | Placebo Comparator | Microcrystalline cellulose placebo encapsulated to appear identical to tolterodine and mirabegron medication will be prepared by a compounding pharmacy. Behavioral self-management education includes written education about timed urination, lifestyle changes, pelvic floor muscle exercises, and urge suppression. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Tolterodine Tartrate ER | Drug | Anticholinergic |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in composite cognitive function over 6 months (24 weeks) of treatment, using a composite cognitive score that incorporates normalized data from all domain-specific cognitive tests. | The composite cognitive score will be calculated as the average of Z-scores from the following individual cognitive tests: a) Auditory Verbal Learning Test (AVLT); b) Oral Trail Making Test (OTMT) part A; c) OTMT part B; d) Digit Span Test; and e) Digit Symbol Substitution Test (DSST). The normative mean of each cognitive test will be subtracted from each participant's component test score, and this difference will be divided by the standard deviation for the appropriate normative sample. After scores from individual tests are transformed to Z scores as a common metric based on normative data, the average Z score from all available tests will be calculated to provide a composite Z score. | Baseline to 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in composite cognitive function over 9 months (36 weeks), using a composite cognitive score that incorporates normalized data from all domain-specific cognitive tests. | The composite cognitive score will be calculated as the average of Z-scores from the following individual cognitive tests: a) Auditory Verbal Learning Test (AVLT); b) Oral Trail Making Test (OTMT) part A; c) OTMT part B; d) Digit Span Test; and e) Digit Symbol Substitution Test (DSST). The normative mean of each cognitive test will be subtracted from each participant's component test score, and this difference will be divided by the standard deviation for the appropriate normative sample. After scores from individual tests are transformed to Z scores as a common metric based on normative data, the average Z score from all available tests will be calculated to provide a composite Z score. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Alison Huang, MD, MAS, MPhil | Contact | 415-514-8697 | alison.huang@ucsf.edu | |
| Ann Chang | Contact | ann.chang@ucsf.edu |
| Name | Affiliation | Role |
|---|---|---|
| Alison Huang, MD, MAS, MPhil | University of California, San Francisco | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Stanford University | Recruiting | Palo Alto | California | 94305 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37085880 | Derived | Huang AJ, Walter LC, Yaffe K, Vittinghoff E, Kornblith E, Schembri M, Chang A, Subak LL. TReating Incontinence for Underlying Mental and Physical Health (TRIUMPH): a study protocol for a multicenter, double-blinded, randomized, 3-arm trial to evaluate the multisystem effects of pharmacologic treatment strategies for urgency-predominant urinary incontinence in ambulatory older women. Trials. 2023 Apr 21;24(1):287. doi: 10.1186/s13063-023-07279-z. |
Not provided
Not provided
The investigative team will make publicly available de-identified individual participant data that underlie the results reported in the publication. This will include data about the baseline characteristics of enrolled participants and any primary or secondary trial outcomes presented in the publication. To gain access, data requestors will be asked to sign a data access agreement.
Starting no later than 6 months following publication of the main trial results (including on-line publication), the investigative team will make publicly available de-identified individual participant data that underlie the results reported in the publication. This will include data about the baseline characteristics of the study participants and any primary or secondary trial outcomes presented in the publication.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Mirabegron | Drug | Beta-3-adrenergic agonist |
|
| Placebo | Drug | matching placebo pill |
|
| Baseline to 9 months (3 months after end of treatment) |
| Change in Auditory Verbal Learning Test total learning score assessed over 6 months (24 weeks) of treatment | The Rey Auditory Verbal Learning Test (AVLT), a widely used test of immediate and delayed verbal learning with established norms in older adults and multiple alternate forms. The total learning score is the sum of words learned from trials 1-5. | Baseline to 6 months (end of treatment) |
| Change in Auditory Verbal Learning Test total learning score assessed over 9 months (36 weeks). | The Rey Auditory Verbal Learning Test (AVLT), a widely used test of immediate and delayed verbal learning with established norms in older adults and multiple alternate forms. The total learning score is the sum of words learned from trials 1-5. | Baseline to 9 months (3 months after end of treatment) |
| Change Auditory Verbal Learning Test delayed free recall score over 6 months (24 weeks) of treatment. | The Rey Auditory Verbal Learning Test (AVLT), a widely used test of immediate and delayed verbal learning with established norms in older adults and multiple alternate forms. Score range of 0-15. | Baseline to 6 months (end of treatment) |
| Change Auditory Verbal Learning Test delayed free recall score over 9 months (36 weeks). | The Rey Auditory Verbal Learning Test (AVLT), a widely used test of immediate and delayed verbal learning with established norms in older adults and multiple alternate forms. Score range of 0-15. | Baseline to 9 months (3 months after end of treatment) |
| Change in Oral Trail Making A score over 6 months (24 weeks) of treatment. | The oral version of the Trail Making Test (OTMT), a timed measure of attention (part A) and executive function (part B) adapted from the written TMT, with established norms for participants across a wide range of ages. Range of 1-150 seconds | Baseline to 6 months (end of treatment) |
| Change in Oral Trail Making A score over 9 months (36 weeks). | The oral version of the Trail Making Test (OTMT), a timed measure of attention (part A) and executive function (part B) adapted from the written TMT, with established norms for participants across a wide range of ages. Range of 1-150 seconds | Baseline to 9 months (3 months after end of treatment) |
| Change in Oral Trail Making B score over 6 months (24 weeks) of treatment. | The oral version of the Trail Making Test (OTMT), a timed measure of attention (part A) and executive function (part B) adapted from the written TMT, with established norms for participants across a wide range of ages. Range of 1-300 seconds. | Baseline to 6 months (end of treatment) |
| Change in Oral Trail Making B score over 9 months (36 weeks). | The oral version of the Trail Making Test (OTMT), a timed measure of attention (part A) and executive function (part B) adapted from the written TMT, with established norms for participants across a wide range of ages. Range of 1-300 seconds. | Baseline to 9 months (3 months after end of treatment) |
| Change in Digit Span reverse component (total correct trials) over 6 months (24 weeks) of treatment. | The Digit Span Reverse (total correct trials), a subtest of the Wechsler Adult Intelligence and Memory Scales, a test of attention and short-term verbal memory, with reliability across in-person and videoconference platforms. Range of 0-14. | Baseline to 6 months (end of treatment) |
| Change in Digit Span reverse component (total correct trials) over 9 months (36 weeks). | The Digit Span Reverse (total correct trials), a subtest of the Wechsler Adult Intelligence and Memory Scales, a test of attention and short-term verbal memory, with reliability across in-person and videoconference platforms. Range of 0-14. | Baseline to 9 months (3 months after end of treatment) |
| Change in Digit Symbol Substitution Test score over 6 months (24 weeks) of treatment. | The Digit Symbol Substitution Test (DSST), a timed, written test assessing incidental memory, visual scanning, and processing speed, in which subjects translate numbers into symbols using a key. Range of 1-133. | Baseline to 6 months (end of treatment) |
| Change in Digit Symbol Substitution Test score over 9 months (36 weeks). | The Digit Symbol Substitution Test (DSST), a timed, written test assessing incidental memory, visual scanning, and processing speed, in which subjects translate numbers into symbols using a key. Range of 1-133. | Baseline 9 months (3 months after end of treatment) |
| Change in frequency of urgency-type incontinence (episodes/week) over 6 months (24 weeks) of treatment. | Frequency and type of incontinence will be assessed using a standardized, 7-day voiding diary. | Baseline to 6 months (end of treatment) |
| Change in frequency of urgency-type incontinence (episodes/week) over 9 months (36 weeks). | Frequency and type of incontinence will be assessed using a standardized, 7-day voiding diary. | Baseline to 9 months (3 months after end of treatment) |
| Change in frequency of any-type incontinence (episodes/week) over 6 months (24 weeks) of treatment. | Frequency and type of incontinence will be assessed using a standardized, 7-day voiding diary. | Baseline to 6 months (end of treatment) |
| Change in frequency of any-type incontinence (episodes/week) over 9 months (36 weeks). | Frequency and type of incontinence will be assessed using a standardized, 7-day voiding diary. | Baseline to 9 months (3 months after end of treatment) |
| Resolution of urinary incontinence from baseline to 6 months (24 weeks). | Frequency and type of incontinence will be assessed using a standardized, 7-day voiding diary. | Baseline to 6 months (end of treatment) |
| Resolution of urinary incontinence from baseline to 9 months (36 weeks). | Frequency and type of incontinence will be assessed using a standardized, 7-day voiding diary. | Baseline to 9 months (3 months after end of treatment) |
| Change in Overactive Bladder Questionnaire Short-Form (OAB-Q SF) Symptom Bother domain score over 6 months (24 weeks) of treatment. | Bothersomeness and impact of overactive bladder symptoms (such as urgency, incontinence, and nocturia) will be assessed using the short-form of the OAB-Q, which generates both a Symptom Bother domain and a Health-Related Quality of Life domain score. | Baseline to 6 months (end of treatment) |
| Change in Overactive Bladder Questionnaire Short-Form (OAB-Q SF) Symptom Bother domain score over 9 months (36 weeks). | Bothersomeness and impact of overactive bladder symptoms (such as urgency, incontinence, and nocturia) will be assessed using the short-form of the OAB-Q, which generates both a Symptom Bother domain and a Health-Related Quality of Life domain score. | Baseline to 9 months (3 months after end of treatment) |
| Change in Overactive Bladder Questionnaire Short-Form (OAB-Q SF) Health-Related Quality of Life domain score over 6 months (24 weeks) of treatment. | Bothersomeness and impact of overactive bladder symptoms (such as urgency, incontinence, and nocturia) will be assessed using the short-form of the OAB-Q, which generates both a Symptom Bother domain and a Health-Related Quality of Life domain score. | Baseline to 6 months (end of treatment) |
| Change in Overactive Bladder Questionnaire Short-Form (OAB-Q SF) Health-Related Quality of Life domain score over 9 months (36 weeks). | Bothersomeness and impact of overactive bladder symptoms (such as urgency, incontinence, and nocturia) will be assessed using the short-form of the OAB-Q, which generates both a Symptom Bother domain and a Health-Related Quality of Life domain score. | Baseline to 9 months (3 months after end of treatment) |
| Change in global sleep quality score over 6 months (24 weeks) of treatment. | Perceived sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), an 18-item validated questionnaire designed to assess sleep quality, latency, efficiency, and problems over a one-week period. | Baseline to 6 months (end of treatment) |
| Change in global sleep quality score over 9 months (36 weeks). | Perceived sleep quality will be assessed using the Pittsburgh Sleep Quality Index (PSQI), an 18-item validated questionnaire designed to assess sleep quality, latency, efficiency, and problems over a one-week period. | Baseline to 9 months (3 months after end of treatment) |
| Change in daytime sleepiness score over 6 months (24 weeks) of treatment. | Daytime sleepiness will be assessed using the Epworth Sleepiness Scale (ESS), an 8-item questionnaire assessing the level of general sleepiness during real life situations in order to distinguish excessive daytime sleepiness from normal daytime sleepiness. | Baseline to 6 months (end of treatment) |
| Change in daytime sleepiness score over 9 months (36 weeks). | Daytime sleepiness will be assessed using the Epworth Sleepiness Scale (ESS), an 8-item questionnaire assessing the level of general sleepiness during real life situations in order to distinguish excessive daytime sleepiness from normal daytime sleepiness. | Baseline to 9 months (3 months after end of treatment) |
| Change in perceived physical function over 6 months (24 weeks) of treatment. | Perceived physical function will be assessed using the PROMIS 10B Adult Physical Function Scale, a 10-item measure that assesses the extent to which daily activities are limited by function of the extremities and central regions. | Baseline to 6 months (end of treatment) |
| Change in perceived physical function over 9 months (36 weeks). | Perceived physical function will be assessed using the PROMIS 10B Adult Physical Function Scale, a 10-item measure that assesses the extent to which daily activities are limited by function of the extremities and central regions. | Baseline to 9 months (3 months after end of treatment) |
| Change in confidence in maintaining balance over 6 months (24 weeks) of treatment. | Confidence in maintaining balance will be assessed using the 15-item Activities Balance Confidence Scale (ABC-S), in which participants self-rate their confidence in keeping balance with performing daily living tasks. | Baseline to 6 months (end of treatment) |
| Change in confidence in maintaining balance over 9 months (36 weeks). | Confidence in maintaining balance will be assessed using the 15-item Activities Balance Confidence Scale (ABC-S), in which participants self-rate their confidence in keeping balance with performing daily living tasks. | Baseline to 9 months (3 months after end of treatment) |
| Change in overall physical performance over 6 months (24 weeks) of treatment. | Physical function will be directly assessed using the Short Physical Performance Battery (SPPB), involving: 1) side-by-side, semi-tandem, and tandem balance tests; 2) a 4-meter walk test; and 3) 5 chair stands, in which participants will be asked to stand up repeatedly from a standard chair to a full extended standing position. | Baseline to 6 months (end of treatment) |
| Change in overall physical performance over 9 months (36 weeks). | Physical function will be directly assessed using the Short Physical Performance Battery (SPPB), involving: 1) side-by-side, semi-tandem, and tandem balance tests; 2) a 4-meter walk test; and 3) 5 chair stands, in which participants will be asked to stand up repeatedly from a standard chair to a full extended standing position. | Baseline to 9 months (3 months after end of treatment) |
| Change in static balance over 6 months (24 weeks) of treatment. | Static balance will additionally be assessed by asking participants to attempt to assume a one-legged stand for 30 seconds. | Baseline to 6 months (end of treatment) |
| Change in static balance from over 9 months (36 weeks). | Static balance will additionally be assessed by asking participants to attempt to assume a one-legged stand for 30 seconds. | Baseline to 9 months (3 months after end of treatment) |
| Change in lower extremity strength measured by chair stand testing over 6 months (24 weeks) of treatment. | Physical strength will be assessed 30-second chair stand, by asking participants to stand up as many times as possible within 30 seconds, with higher number indicating more strength or power. | Baseline to 6 months (end of treatment) |
| Change in lower extremity strength measured by chair stand testing over 9 months (36 weeks). | Physical strength will be assessed 30-second chair stand, by asking participants to stand up as many times as possible within 30 seconds, with higher number indicating more strength or power. | Baseline to 9 months (3 months after end of treatment) |
| Change in depression symptoms over 6 months (24 weeks) of treatment. | Depression symptoms will be assessed using the 15-item short form of the Geriatric Depression Scale-15 (GDS-15), which assesses symptoms of depression over a 1-week period. | Baseline to 6 months (end of treatment) |
| Change in depression symptoms over 9 months (36 weeks). | Depression symptoms will be assessed using the 15-item short form of the Geriatric Depression Scale-15 (GDS-15), which assesses symptoms of depression over a 1-week period. | Baseline to 9 months (3 months after end of treatment) |
| Change in anxiety symptoms over 6 months (24 weeks) of treatment. | Anxiety symptoms will be assessing using the Generalized Anxiety Disorder-7 (GAD7), 7-item short form, questionnaire to assess severity of anxiety symptoms over a 2-week period. | Baseline to 6 months (end of treatment) |
| Change in anxiety symptoms over 9 months (36 weeks). | Anxiety symptoms will be assessing using the Generalized Anxiety Disorder-7 (GAD7), 7-item short form, questionnaire to assess severity of anxiety symptoms over a 2-week period. | Baseline to 9 months (3 months after end of treatment) |
| Change in constipation symptoms over 6 months (24 weeks) of treatment. | Symptoms of constipation as a possible side effect of anticholinergic therapy will be assessed by the 9-item PROMIS Constipation scale of the PROMIS Gastrointestinal Symptoms-Constipation Scale. | Baseline to 6 months (end of treatment) |
| Change in constipation symptoms over 9 months (36 weeks). | Symptoms of constipation as a possible side effect of anticholinergic therapy will be assessed by the 9-item PROMIS Constipation scale of the PROMIS Gastrointestinal Symptoms-Constipation Scale. | Baseline to 9 months (3 months after end of treatment) |
| Change in bowel incontinence symptoms over 6 months (24 weeks) of treatment. | Bowel incontinence as a syndrome that frequently overlaps with urinary incontinence will be assessed using the 4-item PROMIS Bowel Incontinence scale. | Baseline to 6 months (end of treatment) |
| Change in bowel incontinence symptoms over 9 months (36 weeks). | Bowel incontinence as a syndrome that frequently overlaps with urinary incontinence will be assessed using the 4-item PROMIS Bowel Incontinence scale. | Baseline to 9 months (3 months after end of treatment) |
| University of California San Francisco | Recruiting | San Francisco | California | 94115 | United States |
|
| ID | Term |
|---|---|
| D053202 | Urinary Incontinence, Urge |
| D014549 | Urinary Incontinence |
| D053201 | Urinary Bladder, Overactive |
| ID | Term |
|---|---|
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D059411 | Lower Urinary Tract Symptoms |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D001745 | Urinary Bladder Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D000068737 | Tolterodine Tartrate |
| C520025 | mirabegron |
| ID | Term |
|---|---|
| D010665 | Phenylpropanolamine |
| D011412 | Propanolamines |
| D000605 | Amino Alcohols |
| D000438 | Alcohols |
| D009930 | Organic Chemicals |
| D020005 | Propanols |
| D000588 | Amines |
| D001559 | Benzhydryl Compounds |
| D001555 | Benzene Derivatives |
| D006841 | Hydrocarbons, Aromatic |
| D006844 | Hydrocarbons, Cyclic |
| D006838 | Hydrocarbons |
| D003408 | Cresols |
| D010636 | Phenols |
Not provided
Not provided